Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of edoxaban versus standard anticoagulation in children with heart disease at thromboembolic risk
MOH_2018-03-26_002143Phase 3Not yet recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cardiac disease comparing edoxaban with standard of care anticoagulation (2 arms). Primary endpoint: Composite bleeding safety endpoint. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
edoxaban
03
Conditions
cardiac disease
Beyond the preview
Go deeper on MOH_2018-03-26_002143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-26_002143.